Search research articles
Contact Us
Filters
Showing results (11-20 of 27) with videos related to
Page
of 3
Sort By:
Schizophrenia Research
|
November 10, 2009
The effect of atypical antipsychotics on pituitary gland volume in patients with first-episode psychosis: a longitudinal MRI study
John-Paul Nicolo, Gregor E Berger, Belinda A Garner, et al.
The Journal of Clinical Psychiatry
|
November 28, 2008
Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years
Gregor E Berger, Tina-Marie Proffitt, Mirabel McConchie, et al.
Schizophrenia Research
|
August 7, 2025
Therapy process factors in early psychosis: The effect of working alliance on clinical symptoms and cognitive biases in Ultra High Risk young people
Paulina Bagrowska, Cassandra Wannan, Andrea Polari, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry
|
December 15, 2010
Phospholipase A₂ activity in first episode schizophrenia: associations with symptom severity and outcome at week 12
Stefan Smesny, Christina Kunstmann, Sebastian Kunstmann, et al.
Biological Psychiatry Global Open Science
|
July 23, 2025
White Blood Cell Proportions Are Associated With Response to Psychosocial Therapy in Young People at Ultra-High Risk for Psychosis
Lauren F Barker, Allan F McRae, Hok Pan Yuen, et al.
Schizophrenia Research. Cognition
|
March 4, 2021
Cognitive ability and metabolic physical health in first-episode psychosis
Sarah Whitson, Brian O'Donoghue, Robert Hester, et al.
Brain, Behavior, and Immunity
|
February 27, 2026
Effects of 6-months of SSRI use on DNA-methylation and gene expression in blood
Lauren F Barker, Allan F McRae, Hok Pan Yuen, et al.
Early Intervention in Psychiatry
|
June 30, 2021
Cannabidiol for at risk for psychosis youth: A randomized controlled trial
G Paul Amminger, Ashleigh Lin, Melissa Kerr, et al.
The Lancet. Psychiatry
|
August 3, 2019
The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial
Christopher G Davey, Andrew M Chanen, Sarah E Hetrick, et al.
Psychiatry Research
|
May 29, 2024
Erythrocyte membrane fatty acid concentrations and myelin integrity in young people at ultra-high risk of psychosis
Melissa Collins, Cali Bartholomeusz, Cristina Mei, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 27) with videos related to
Sort By:
Page
of 3
Schizophrenia Research
|
November 10, 2009
The effect of atypical antipsychotics on pituitary gland volume in patients with first-episode psychosis: a longitudinal MRI study
John-Paul Nicolo, Gregor E Berger, Belinda A Garner, et al.
The Journal of Clinical Psychiatry
|
November 28, 2008
Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years
Gregor E Berger, Tina-Marie Proffitt, Mirabel McConchie, et al.
Schizophrenia Research
|
August 7, 2025
Therapy process factors in early psychosis: The effect of working alliance on clinical symptoms and cognitive biases in Ultra High Risk young people
Paulina Bagrowska, Cassandra Wannan, Andrea Polari, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry
|
December 15, 2010
Phospholipase A₂ activity in first episode schizophrenia: associations with symptom severity and outcome at week 12
Stefan Smesny, Christina Kunstmann, Sebastian Kunstmann, et al.
Biological Psychiatry Global Open Science
|
July 23, 2025
White Blood Cell Proportions Are Associated With Response to Psychosocial Therapy in Young People at Ultra-High Risk for Psychosis
Lauren F Barker, Allan F McRae, Hok Pan Yuen, et al.
Schizophrenia Research. Cognition
|
March 4, 2021
Cognitive ability and metabolic physical health in first-episode psychosis
Sarah Whitson, Brian O'Donoghue, Robert Hester, et al.
Brain, Behavior, and Immunity
|
February 27, 2026
Effects of 6-months of SSRI use on DNA-methylation and gene expression in blood
Lauren F Barker, Allan F McRae, Hok Pan Yuen, et al.
Early Intervention in Psychiatry
|
June 30, 2021
Cannabidiol for at risk for psychosis youth: A randomized controlled trial
G Paul Amminger, Ashleigh Lin, Melissa Kerr, et al.
The Lancet. Psychiatry
|
August 3, 2019
The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial
Christopher G Davey, Andrew M Chanen, Sarah E Hetrick, et al.
Psychiatry Research
|
May 29, 2024
Erythrocyte membrane fatty acid concentrations and myelin integrity in young people at ultra-high risk of psychosis
Melissa Collins, Cali Bartholomeusz, Cristina Mei, et al.
Page
of 3